Share. Connect. Create. Grow. · Socialiya
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company's first prod...

BUSINESS NEWS August 07, 2026

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company's first product on the market.

9 views 0 likes 0 comments
Share:
Replimune secures FDA approval for Tudriqev on its third attempt, making it the company's first product on the market.

Author: Barron's

Read Original Article

Related News

Latest News

Advertisement

Top Categories

Advertisement
Advertisement
Advertisement
Advertisement